Peroxisome Proliferator-activated Receptor Gamma Activators Inhibit Gene Expression and Migration in Human Vascular Smooth Muscle Cells

Overview

Journal Circ Res

Specialty Cardiology & Vascular Diseases

Date 1998 Dec 1

PMID 9831704

Citations 129

Authors

N Marx

U Schonbeck

M A Lazar

P Libby

J Plutzky

Affiliations

Soon will be listed here.

Abstract

Migration of vascular smooth muscle cells (VSMCs) plays an important role in atherogenesis and restenosis after arterial interventions. The expression of matrix metalloproteinases (MMPs), particularly MMP-9, contributes to VSMC migration. This process requires degradation of basal laminae and other components of the arterial extracellular matrix. Peroxisome proliferator-activated receptors (PPARs), members of the nuclear receptor family, regulate gene expression after activation by various ligands. Recent studies have suggested opposing effects of PPAR gamma (PPARgamma) activation on atherogenesis. The present study tested the hypotheses that human VSMCs express PPAR alpha (PPARalpha) and PPARgamma and that PPAR agonists in VSMCs modulate MMP-9 expression and activity, as well as VSMC migration. Human VSMCs expressed PPARalpha and PPARgamma mRNA and protein. Treatment of VSMCs with the PPARgamma ligands troglitazone and the naturally occurring 15-deoxy-Delta12, 14-prostaglandin J2 (15d-PGJ2) decreased phorbol 12-myristate 13-acetate-induced MMP-9 mRNA and protein levels, as well as MMP-9 gelatinolytic activity in the supernatants in a concentration-dependent manner. Six different PPARalpha activators lacked such effects. Addition of prostaglandin F2alpha, known to limit PPARgamma activity, diminished the MMP-9 inhibition seen with either troglitazone or 15d-PGJ2, further implicating PPARgamma in these effects. Finally, troglitazone and 15d-PGJ2 inhibited the platelet-derived growth factor-BB-induced migration of VSMCs in vitro in a concentration-dependent manner. PPARgamma activation may regulate VSMC migration and expression and activity of MMP-9. Thus, PPARgamma activation in VSMCs, via the antidiabetic agent troglitazone or naturally occurring ligands, may act to counterbalance other potentially proatherosclerotic PPARgamma effects.

Citing Articles

Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.

Villegas-Vazquez E, Marin-Carrasco F, Reyes-Hernandez O, Baez-Gonzalez A, Bustamante-Montes L, Padilla-Benavides T Front Oncol. 2025; 14:1514120.

PMID: 39876896 PMC: 11772297. DOI: 10.3389/fonc.2024.1514120.

Matrix Metalloproteinase-9 Signaling Regulates Colon Barrier Integrity in Models of HIV Infection.

Ohene-Nyako M, Persons A, Forsyth C, Keshavarzian A, Napier T J Neuroimmune Pharmacol. 2024; 19(1):57.

PMID: 39499375 DOI: 10.1007/s11481-024-10158-2.

PPARs in Clinical Experimental Medicine after 35 Years of Worldwide Scientific Investigations and Medical Experiments.

Skoczynska A, Oldakowska M, Dobosz A, Adamiec R, Gritskevich S, Jonkisz A Biomolecules. 2024; 14(7).

PMID: 39062500 PMC: 11275227. DOI: 10.3390/biom14070786.

Prenatal exposure to alcohol: mechanisms of cerebral vascular damage and lifelong consequences.

Saha P, Mayhan W Adv Drug Alcohol Res. 2024; 2:10818.

PMID: 38390614 PMC: 10880760. DOI: 10.3389/adar.2022.10818.

Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease.

Fuior E, Zvintzou E, Filippatos T, Giannatou K, Mparnia V, Simionescu M Biomedicines. 2023; 11(10).

PMID: 37893070 PMC: 10604751. DOI: 10.3390/biomedicines11102696.

References

Reginato M, Krakow S, Bailey S, Lazar M . Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. J Biol Chem. 1998; 273(4):1855-8. DOI: 10.1074/jbc.273.4.1855. View

Schwartz S, Raskin P, Fonseca V, Graveline J . Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med. 1998; 338(13):861-6. DOI: 10.1056/NEJM199803263381302. View

Forman B, Tontonoz P, Chen J, Brun R, Spiegelman B, Evans R . 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995; 83(5):803-12. DOI: 10.1016/0092-8674(95)90193-0. View

Galis Z, Sukhova G, Lark M, Libby P . Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994; 94(6):2493-503. PMC: 330083. DOI: 10.1172/JCI117619. View

Law R, Meehan W, Xi X, Graf K, Wuthrich D, Coats W . Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 1996; 98(8):1897-905. PMC: 507630. DOI: 10.1172/JCI118991. View

Nagy L, Tontonoz P, Alvarez J, Chen H, Evans R . Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 1998; 93(2):229-40. DOI: 10.1016/s0092-8674(00)81574-3. View

Cominacini L, Garbin U, Pasini A, Campagnola M, Davoli A, Foot E . Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes. 1998; 47(1):130-3. DOI: 10.2337/diab.47.1.130. View

Kliewer S, Lenhard J, Willson T, Patel I, Morris D, Lehmann J . A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 1995; 83(5):813-9. DOI: 10.1016/0092-8674(95)90194-9. View

Bendeck M, Zempo N, Clowes A, Galardy R, Reidy M . Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994; 75(3):539-45. DOI: 10.1161/01.res.75.3.539. View

10.

Schoonjans K, LAINE B, Fruchart J, Auwerx J, Staels B . Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem. 1994; 269(49):31012-8. View

11.

Rentoumis A, Chatterjee V, Madison L, Datta S, Gallagher G, DeGroot L . Negative and positive transcriptional regulation by thyroid hormone receptor isoforms. Mol Endocrinol. 1990; 4(10):1522-31. DOI: 10.1210/mend-4-10-1522. View

12.

Fabunmi R, Baker A, Murray E, Booth R, Newby A . Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. Biochem J. 1996; 315 ( Pt 1):335-42. PMC: 1217192. DOI: 10.1042/bj3150335. View

13.

Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B . A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell. 1996; 85(3):403-14. DOI: 10.1016/s0092-8674(00)81118-6. View

14.

Jiang C, Ting A, Seed B . PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998; 391(6662):82-6. DOI: 10.1038/34184. View

15.

Marx N, Sukhova G, Murphy C, Libby P, Plutzky J . Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol. 1998; 153(1):17-23. PMC: 1852950. DOI: 10.1016/s0002-9440(10)65540-x. View

16.

Pfahl M . Nuclear receptor/AP-1 interaction. Endocr Rev. 1993; 14(5):651-8. DOI: 10.1210/edrv-14-5-651. View

17.

Brown D, Hibbs M, Kearney M, Loushin C, Isner J . Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation. 1995; 91(8):2125-31. DOI: 10.1161/01.cir.91.8.2125. View

18.

Inzucchi S, Maggs D, Spollett G, Page S, Rife F, Walton V . Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998; 338(13):867-72. DOI: 10.1056/NEJM199803263381303. View

19.

Ricote M, Li A, Willson T, Kelly C, Glass C . The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998; 391(6662):79-82. DOI: 10.1038/34178. View

20.

Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre A, Saladin R . The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem. 1997; 272(30):18779-89. DOI: 10.1074/jbc.272.30.18779. View